title: Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia.
abstract: OBJECTIVE
  The aim of the presented study was to assess plasma glycogen phosphorylase BB (GPBB) concentrations in acute leukemia patients treated with anthracycline containing chemotherapy.
  
  
  BACKGROUND
  Anthracyclines represent the highest risk for development of cardiotoxicity. GPBB belongs to proposed biomarkers of cardiac injury with a very limited experience in this context.
  
  
  METHODS
  Totally, 24 adult patients with acute leukemia were enrolled. Plasma GPBB concentrations were measured by ELISA at diagnosis (before chemotherapy), after first chemotherapy with anthracyclines and 6 months after the completion of treatment. The cut-off value for GPBB positivity was 10.00 µg/L as recommended by the manufacturer.
  
  
  RESULTS
  Before chemotherapy, the mean plasma GPBB concentration was 5.25±3.81 µg/L, increased above the cut-off in 1 patient (4.2 %). After the first chemotherapy, the mean GPBB was 6.61±5.54 µg/L, positive in 7 (29.2 %) patients. Six months after treatment, the mean GPBB was 10.06±11.41 µg/L, positive in 8 (33.3 %) patients. Six months after treatment, we found a significant correlation between elevation in GPBB and diastolic left ventricular dysfunction on echocardiography (r=0.621; p<0.0001). The differences in plasma GPBB between healthy blood donors and patients treated for acute leukemia were statistically significant (p<0.01 in all cases).
  
  
  CONCLUSIONS
  Our results suggested that GPBB could become a potential biomarker for detection of acute and chronic cardiotoxicity associated with anthracycline containing chemotherapy. The predictive value for development of treatment-related cardiomyopathy in future is not clear and will be evaluated during the follow-up. Further studies are needed to define the potential role of GPBB and other biomarkers in the assessment of chemotherapy-induced cardiotoxicity (Ref. 21). Text in PDF www.elis.sk.
authors: J M
authors: JM
authors: Horacek
authors: L
authors: L
authors: Jebavy
authors: M
authors: M
authors: Vasatova
authors: R
authors: R
authors: Pudil
authors: M
authors: M
authors: Tichy
authors: M
authors: M
authors: Jakl
authors: J
authors: J
authors: Maly
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D024981:Glycogen Phosphorylase / Q000097:blood*; D006331:Heart Diseases / Q000139:chemically induced* / Q000201:enzymology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged
chemical_list: D018943:Anthracyclines; D015415:Biomarkers; D024981:Glycogen Phosphorylase; C528446:glycogen phosphorylase BB, human
keywords: glycogen phosphorylase BB, cardiac toxicity, chemotherapy, anthracyclines, acute leukemia.